Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Novel KAT6B-KANSL1 Fusion Gene Identified by RNA Sequencing in Retroperitoneal Leiomyoma with t(10;17)(q22;q21)

  • Ioannis Panagopoulos ,

    Affiliations: Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway, Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway

  • Ludmila Gorunova,

    Affiliations: Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway, Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway

  • Bodil Bjerkehagen,

    Affiliation: Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

  • Sverre Heim

    Affiliations: Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway, Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway

Novel KAT6B-KANSL1 Fusion Gene Identified by RNA Sequencing in Retroperitoneal Leiomyoma with t(10;17)(q22;q21)

  • Ioannis Panagopoulos, 
  • Ludmila Gorunova, 
  • Bodil Bjerkehagen, 
  • Sverre Heim


Retroperitoneal leiomyoma is a rare type of benign smooth muscle tumor almost exclusively found in women and with histopathological features similar to uterine leiomyomas. The pathogenesis of retroperitoneal leiomyoma is unclear and next to nothing is known about the cytogenetics and molecular genetics of the tumor. Here we present the first cytogenetically analyzed retroperitoneal leiomyoma. It had a t(10;17)(q22;q21) as the sole chromosomal abnormality. Using RNA-Sequencing and the ‘grep’ command to search the fastq files of the sequence data we found that the translocation resulted in fusion of the genes KAT6B (10q22) with KANSL1 (17q21). RT-PCR together with direct (Sanger) sequencing verified the presence of a KAT6B-KANSL1 fusion transcript. No reciprocal KANSL1-KAT6B transcript was amplified suggesting that it was either absent or unexpressed. The KAT6B-KANSL1 fusion transcript consists of exons 1 to 3 of KAT6B and exons 11 to 15 of KANSL1, is 3667 bp long, has a 1398 bp long open reading frame, and codes for a 466 amino acid residue protein. The corresponding KAT6B-KANSL1 protein contains the NEMM domain (including the linker histone H1/H5, domain H15) of KAT6B and the PEHE domain of KANSL1. The function of the fusion protein might be regulation of transcription with an affinity for chromatin (linker histone H1/H5) and interaction with the HAT domain of KAT8 (PEHE domain). The tumor expressed HMGA2 and HMGA1 even though 12q14-15 and 6p looked normal by G-banding analysis. The tumor also expressed MED12 in the absence of exon 2 mutations. Overall, the data show that the examined retroperitoneal leiomyoma resembles a subset of uterine leiomyomas in terms of histology and genetics.


Leiomyomas are benign tumors that display smooth muscle differentiation, the most common type being uterine leiomyoma. Extrauterine leiomyomas are rare, may arise in any anatomic site, and may be difficult to distinguish from malignancies [1]. Unusual growth patterns have been reported; they include benign metastasizing leiomyoma, disseminated peritoneal leiomyomatosis, intravenous leiomyomatosis, parasitic leiomyoma, and retroperitoneal leiomyoma [1].

Retroperitoneal leiomyomas are almost exclusively found in women [24]. They may enlarge considerably before they become symptomatic and are often detected incidentally at a routine check-up or during autopsy [5]. Common symptoms include discomfort, fatigue, and back pain [4]. The pathogenesis is unknown and it is not clear whether the tumors represent metastatic or primary lesions [6] and whether they arise from hormonally sensitive smooth muscle elements [2] or from the embryonal remnants of Müllerian or Wolffian ducts [7]. In terms of histology, retroperitoneal leiomyomas resemble their uterine counterparts in often having hyaline fibrosis, alternating myxoid change or trabecular matterns, and positivity for estrogen and progesterone receptors [24]. They show low mitotic activity with little to no atypia, no necrosis, and immunohistochemical features consistent with smooth muscle tumors with positive staining for desmin and smooth muscle–specific actin (SMA) but negative staining for C-KIT and CD34; the latter finding rules out gastrointestinal stromal tumor [4].

No information about the cytogenetics and molecular genetics of retroperitoneal leiomyomas is given in the “Mitelman database of chromosome aberrations in cancer” (, database last updated on May 13, 2014) nor is any provided in the 2013 edition of “WHO classification of tumours of soft tissue and bone” [8].

Recently, however, mutations in exon 2 of the mediator complex subunit 12 (MED12) gene were found in 10 out of 29 (34%) leiomyomas/leiomyomatoses in pelvic/retroperitoneal sites [9]. Since mutations in exon 2 of MED12 are found also in the majority (50–80%) of uterine leiomyomas [913], Schwetye et al. [9] concluded that “smooth muscle tumors in pelvic/retroperitoneal sites are subject to the same mutational changes as those of uterine myometrium, and [that] these mutations may precede the gross or histological development of a leiomyoma” [9].

Most uterine leiomyomas are cytogenetically characterized by the presence of one or more of the following cytogenetic aberrations: t(12;14)(q15;q23–24), del(7)(q21.2q31.2), rearrangements involving 6p21, 10q, and 1p, trisomy 12, deletions of 3q, and changes of the X chromosome [14]. Besides, 34 out of 495 (7%) uterine leiomyomas have aberrations involving the q arm of chromosome 10 and in 25 of these tumors the breakpoint targets chromosome band 10q22 (, Database last updated on May 13, 2014). Moore et al. [15] studied four uterine leiomyomas with rearrangements of 10q and 17q and found disruption of the KAT6B gene in 10q22 (also known as MORF and MYST4) in all of them. They mapped the breakpoint in 17q21 in three tumors but detected no fusion gene. The KAT6B gene encodes a member of the MYST family of histone acetylases (histone acetyltrasferase) and was shown to be in-frame fused to CREBBP in acute myeloid leukemia with t(10;16)(q22;p13) [16].

Here we present the first cytogenetically analyzed retroperitoneal leiomyoma. The tumor had a t(10;17)(q22;q21) as the sole karyotypic aberration. Using RNA-sequencing (RNA-Seq) and the “grep” command we could demonstrate that the molecular consequence of the translocation was fusion of KAT6B with the KANSL1 gene (official full name: KAT8 regulatory NSL complex subunit 1) from 17q21. The tumor was also investigated for expression of HMGA2, HMGA1, and MED12 as well as for possible mutations in exon 2 of MED12.

Materials and Methods

Ethics Statement

The study was approved by the regional ethics committee (Regional komité for medisinsk forskningsetikk Sør-Øst, Norge,, and written informed consent was obtained from the patient.

Case History

A 45-year-old previously healthy woman presented with abdominal discomfort and a large retroperitoneal tumor was detected and resected. Microscopic examination showed fascicles of long spindle cells with eosinophilic cytoplasm surrounded by a loose fibrous matrix (Fig. 1). Immunohistochemistry demonstrated positive staining for SMA, desmin, and estrogen and progesterone receptors, but was negative for the cytokeratin cocktail AE1/AE3, CD68, CD99, CD117, EMA, HMB-45, S-100, and Melan-A. Neither atypia nor necrosis was found. There were very few mitotic figures (0–1/10 high power fields). The histological diagnosis was leiomyoma. After surgery the patient has had no recurrence (4 years).

Figure 1. Histological examination of the retroperitoneal leiomyoma.

A) H&E-stained slide showing the tumor spindle cells with eosinophilic cytoplasm without atypia surrounded by loose fibrous stroma. B) Immunoexpression of desmin. C) Immunoexpression of SMA.

G-banding and Karyotyping

Fresh tumor tissue was received and analyzed cytogenetically as part of our diagnostic routine. The sample was disaggregated mechanically and enzymatically with collagenase II (Worthington, Freehold, NJ, USA). The resulting cells were cultured and harvested using standard techniques. Chromosome preparations were G-banded with Wright stain and examined. The karyotype was written according to The International System for Human Cytogenetic Nomenclature (ISCN) 2009 guidelines [17].

High-throughput Paired-end RNA-sequencing

Tumor tissue adjacent to that used for cytogenetic analysis and histologic examination had been frozen and stored at -80°C. Total RNA was extracted using Trizol reagent according to the manufacturer’s instructions (Invitrogen, Oslo, Norway) with a homogenizer (Omni THQ Digital Tissue Homogenizer, Kennesaw, GA, USA). The RNA quality was evaluated using the Experion Automated Electrophoresis System (Bio-Rad Laboratories, Oslo, Norway). The RNA Quality Indicator (RQI) was 6.7 and the electropherogram of the sample obtained by the Experion system is shown in Fig. 2. Three µg of total RNA were sent for high-throughput paired-end RNA-sequencing at the Norwegian Sequencing Centre, Ullevål Hospital ( The RNA was sequenced using an Illumina HiSeq 2000 instrument and the Illumina software pipeline was used to process image data into raw sequencing data. The regular TruSeq library preparation protocol was used ( and the reads obtained had a length of 100 base pairs. A total of 74 million reads were obtained. The quality of the raw sequence data was assessed using FastQC software ( The softwares FusionMap ( [18] and FusionFinder ( [19] were used for the discovery of fusion transcripts. In addition, the “grep” command ( was used to search the fastq files of the sequence data ( for KAT6B sequence (NM_012330 version 3). FusionMap was run on a PC with Windows 7 Professional as the operative system. FusionFinder and “grep” command were run on a PC with Bio-Linux 7 as the operating system [20].

Figure 2. Electropherogram showing the quality of the extracted RNA from the retroperitoneal leiomyoma which was used for RNA-Seq and RT-PCR experiments.

The RNA was run on the Experion automated electrophoresis system using an Experion RNA StdSens analysis chip. The RQI value 6.7 was automatically calculated by the Experion.

Molecular Genetic Analyses

Two µg of total RNA were reverse-transcribed in a 20 µL reaction volume using iScript Advanced cDNA Synthesis Kit for RT-qPCR according to the manufacturer’s instructions (Bio-Rad Laboratories). The cDNA was diluted to 50 µL and 1 µL was used as template in subsequent PCR assays. The 25 µL PCR volumes contained 12.5 µL of Premix Taq (Takara Bio Europe/SAS, Saint-Germain-en-Laye, France), 1 µL of diluted cDNA, and 0.2 µM of each of the forward and reverse primers. The PCRs were run on a C-1000 Thermal cycler (Bio-Rad Laboratories). The PCR conditions for all amplifications except HMGA1 were: an initial denaturation at 94°C for 30 sec followed by 35 cycles of 7 sec at 98°C and 2 min at 68°C, and a final extension for 5 min at 68°C. For the detection of the KAT6B-KANSL1 fusion transcript, two forward KAT6B primers, MORF-1234F (5′-GCT TAG ATG GCA AAG GGG CAC CTC-3′) and MORF-1261F (5′-ATC CCA GTG CAT TCC CAT CCT CG-3′), and two reverse KANSL1 primers, KANSL1–2969R1 (5′-GTG GCA CAC TCG TGG TCC ACA GC-3′) and KANSL1–2900R1 (5′-AGG CTG CGT CGG ATA GGT CCT CA-3′), were used. The following primer combinations were applied: 1) MORF-1234F together with the primer KANSL1–2969R1, 2) MORF-1234F together with the primer KANSL1–2900R1, 3) MORF-1261F together with the primer KANSL1–2969R1, and 4) MORF-1261F together with the primer KANSL1–2900R1.

For the detection of a possible reciprocal KANSL1-KAT6B, nested PCR was used. In the first round, the KANSL1 forward primer KANSL1–2341F1 (5′-GGC ACA AAT TGG TCA GCT CCT TCC T-3′) and the reverse KAT6B primer MORF-1591R1 (5′-GAA AGT GGT GGG TCA CAG CAT TCC A-3′) were used. One microliter of the first PCR was used as template in the nested PCR together with primers KANSL1–2407F1 (5′-GGA CCC ACA GGC AGC ACT TAG ACG-3′) and MORF-1483R1 (5′-CAT TCG ATG CAC TGC CAC CTT AAG G-3′).

For the expression of HMGA2, two PCR amplifications were performed. The primer set HMGA2–846F1 (5′-CCA CTT CAG CCC AGG GAC AAC CT-3′)/HMGA2–1021R (5′-CCT CTT GGC CGT TTT TCT CCA GTG-3′) was used for the amplification of transcripts of HMGA2 exons 1–3. The primer set HMGA2–846F1/HMGA2–1112R (5′-CCT CTT CGG CAG ACT CTT GTG AGG A-3′) was used for transcripts of HMGA2 containing exons 1–5. For the expression of HMGA1, the primers HMGA1–284F1 (5′-CAG CCA TCA CTC TTC CAC CTG C-3′) and HMGA1–648R1 (5′-CTG TCC AGT CCC AGA AGG AAG CT-3′) were used. The PCR conditions were: an initial denaturation at 94°C for 30 sec followed by 35 cycles of 7 sec at 98°C, 30 sec at 55°C and 1 min at 72°C, and a final extension for 5 min at 72°C.

For the expression of MED12 and the detection of possible mutation in exon 2 of MED12, the primers MED12-Ex1-F (5′-TTA CCC TCA GGA CCC CAA ACA G-3′) and MED12-Ex3-R (5′-TGC AAT AAT GCT GCT GAA GTT GG-3′) were used.

Three µL of the PCR products were stained with GelRed (Biotium), analyzed by electrophoresis through 1.0% agarose gel, and photographed. The remaining PCR products were purified using the Qiagen PCR purification kit (Qiagen) and direct sequencing was performed using the light run sequencing service of GATC Biotech ( The BLAST software ( was used for computer analysis of sequence data.


To detect the HMGA2 protein, immunostaining was performed as described previously [21].



The G-banding analysis yielded a karyotype with a single chromosome abnormality: 46,XX,t(10;17)(q22;q21)[10]/46,XX[5] (Fig. 3A).

Figure 3. Cytogenetic results and bioinformatic analyses of the RNA-Seq data of the retroperitoneal leiomyoma.

A) Partial karyotype showing the der(10)t(10;17)(q22;q21) and der(17)t(10;17)(q22;q21) together with the corresponding normal chromosome homologs; breakpoint positions are indicated by arrows. B) The 101 bp sequence obtained from the raw data of RNA-Seq using the command “grep”. The search term “TACCCCATGAGAAAGACCAG” is underlined. C) The results of BLAT search genome using the 101 bp sequence (see B) on the human genome browser-hg19 assembly ( D) Ideogram of chromosome 10 showing that nucleotides 1–43 of the 101 bp sequence (see B) are mapped on band q22.2 (red vertical line). E) The result of BLAT search (your sequence from BLAT search) showed that nucleotides 1–43 are part of the KAT6B coding region. F) Ideogram of chromosome 17 showing that nucleotides 41–101 of the sequence from B are mapped on band q21.3 (red vertical line). G) The result of BLAT search (your sequence from BLAT search) shows that the nucleotides are part of the KANSL1 coding region.

High-throughput Paired-end RNA-sequencing Analysis

FusionMap and FusionFinder identified 609 and 85 potential fusion transcripts, respectively (S1 and S2 Tables), but none of them was related to the chromosome aberration, t(10;17)(q22;q21). Nor was KAT6B found to be a partner in any of the detected fusion transcripts (S1 and S2 Tables). KAT6B was reported to be targeted in four uterine leiomyomas with a chromosome rearrangement involving 10q22 and 17q21–24 and the breakpoint was mapped to the third intron of the KAT6B gene [15]. Since the raw sequence data were in the text-based fastq format, we used the “grep” command-line utility to search for sequences which contained part of the third exon of KAT6B (nucleotides 444–1322 in the sequence with accession number NM_012330 version 3). The search term was “TACCCCATGAGAAAGACCAG” that corresponded to the last 20 nucleotides of exon 3 of KAT6B (nt 1303–1322 in the sequence with accession number NM_012330 version 3). The search term extracted only the following 101 bp long sequence: “CTCGCTCCCACCTGTCAGCCTTCTACCCCATGAGAAAGACCAGCAGCAGCCAGTAAGGAGGTGAAGGGGAGAGAGCTCATTCGATATTAACAACATTGTCA” (Fig. 3B). BLAT of this sequence on the human genome browser-hg19 assembly ( showed that nucleotides 1–43 mapped on chromosome 10 at position 76603194–76603236, on 10q22.2 in a coding region of KAT6B, whereas nucleotides 41–101 mapped on chromosome 17 at position 44111594–44111654, on 17q21.31 in coding region of KANSL1 (Fig. 3C‐G). These data were verified when we used the BLAST algorithm ( to compare the 101 bp sequence with the KAT6B reference sequence NM_012330 version 3 and the KANSL1 reference sequence NM_015443 version 3. The nucleotides “CTCGCTCCCACCTGTCAGCCTTCTACCCCATGAGAAAGACCAG” correspond to nt 1280–1322 of the KAT6B reference sequence NM_012330 version 3 and the nucleotides “CAGCAGCCAGTAAGGAGGTGAAGGGGAGAGAGCTCATTCGATATTAACAACATTGTCA” correspond to nt 2715–2772 of the KANSL1 reference sequence NM_015443 version 3.

Thus, the 101 bp sequence which was obtained with the “grep”command was part of a chimeric KAT6B-KANSL1 transcript which could have been generated by the chromosome abnormality t(10;17)(q22;q21) since KAT6B is located on 10q22.2 and KANSL1 is located in 17q21.31.

Molecular Genetic Confirmation of the KAT6B-KANSL1 Fusion

To verify the data obtained with the “grep” command, PCR amplifications were performed using two forward KAT6B and two reverse KANSL1 primers corresponding to sequences located upstream and downstream of the putative breakpoint, respectively. RT-PCR with all four primer combinations, MORF-1234F/KANSL1–2969R1, MORF-1234F/ KANSL1–2900R1, MORF-1261F/KANSL1–2969R1, and MORF-1261F/KANSL1–2900R1, amplified cDNA fragments strongly suggesting the presence of a KAT6B-KANSL1 fusion transcript in the examined tumor (Fig. 4A, lanes 1–4). Sequencing of the amplified cDNA fragment obtained with the MORF-1234F/KANSL1–2969R1 primer set showed that it was a KAT6B-KANSL1 chimeric cDNA fragment in which exon 3 of KAT6B (nucleotide 1322 accession number NM_012330 version 3) was in-frame fused to exon 11 of KANSL1 (nucleotide 2715 accession number NM_015443 version 3) (Fig. 4B). A reciprocal KANSL1-KAT6B transcript was not amplified suggesting that it was absent or not expressed (data not shown).

Figure 4. Expression of KAT6B-KANSL1, HMGA2, HMGA1, and MED12 in the retroperitoneal leiomyoma.

A) Gel electrophoresis of the amplified products. Lanes 1–4: RT-PCR with primer combinations MORF-1234F/KANSL1–2969R1, MORF1234F/KANSL1–2900R1, MORF-1261F/KANSL1–2969R1, and MORF-1261F/KANSL1–2900R1, respectively. The amplified cDNA fragments indicated the presence of a KAT6B-KANSL1 fusion transcript in the examined tumor. Lanes 5 and 6: RT-PCR with primer combinations HMGA2–846F1/HMGA2–1021R and HMGA2–846F1/HMGA2–1112R, respectively, showed expression of HMGA2. Lane 7: RT-PCR with primers MED12-Ex1-F/MED12-Ex3-R indicated expression of MED12. Lane 8: RT-PCR with primer set HMGA1–284F1/HMGA1–648R indicated expression of HMGA1. B) Partial sequence chromatogram of the amplified cDNA fragment showing that exon 3 of KAT6B is fused to exon 11 of KANSL1. C) Tumor tissue showing widespread immunohistochemical nuclear staining for the HMGA2 protein.

Expression of HMGA2 and HMGA1

RT-PCR with the primer sets HMGA2–846F1/HMGA2–1021R and HMGA2–846F1/HMGA2–1112R amplified cDNA fragments from the tumor (Fig. 4A, lanes 5–6). The results indicated that a full length HMGA2 transcript was expressed in the examined leiomyoma although no chromosome 12q rearrangements were seen cytogenetically. Similarly, RT-PCR with the primer set HMGA1–284F1/HMGA1–648R1 amplified a HMGA1 cDNA fragment indicating that the HMGA1 gene was expressed in the tumor (Fig. 4A, lane 8). The immunohistochemical analysis demonstrated nuclear expression of the HMGA2 protein (Fig. 4C).

Expression of MED12 and Mutations in Exon 2 of MED12

RT-PCR with the primers MED12-Ex1-F/MED12-Ex3-R amplified a 163 bp cDNA fragment which contained part of exon 1, the entire exon 2, and part of exon 3 of the MED12 gene suggesting that MED12 is expressed (Fig. 4A, lane 7). Sequencing of the PCR product did not show any mutation in the amplified cDNA fragment of MED12 (data not shown).


We used RNA sequencing and the “grep” command on raw RNA sequencing data to identify a KAT6B-KANSL1 fusion gene in a retroperitoneal leiomyoma carrying a t(10;17)(q22;q21) chromosome translocation. The principle of this approach is based on the fact that RNA sequencing data produced on high throughput sequence platforms come as fastq format files (filename.fastq). Fastq file is a text-based format ( and can be searched using the “grep” command-line utility ( to look for specific expressions. By default “grep” displays the lines where matches occur. Using as “specific expression” a sequence of, for example, 20 nucleotides, the “grep” command will display all the lines (sequence reads) which contain the 20 nucleotides of the specific expression. The sequences obtained by “grep” could be further analyzed using BLAST ( and BLAT ( algorithms and aligned against a known sequence database such as the human genomic plus transcript database. This approach was used before to detect the fusion transcripts KAT6A-CREBBP and CIC-DUX4 as well as a novel alternative transcript of CSF1 in an acute myeloid leukemia, a small round cell sarcoma, and tenosynovial giant cell tumors, respectively [2224].

Our hypothesis was that the translocation of the examined leiomyoma had created a genomic breakpoint in intron 3 of KAT6B, similar to what was found in the four uterine leiomyomas reported by Moore et al. [15], one of which had a balanced t(10;17)(q22;q23) as the sole chromosomal abnormality. This would enable a fusion of the first 3 exons of KAT6B with a gene located in 17q21 to generate a chimeric transcript. Using the search term “TACCCCATGAGAAAGACCAG” which corresponds to the last 20 nucleotides of exon 3 of KAT6B (nt 1303–1322 in the sequence with accession number NM_012330 version 3), the “grep” command displayed a 101 bp chimeric KAT6B-KANSL1 sequence (Fig. 2B). Subsequent RT-PCR and Sanger sequencing of the PCR amplified fragments verified the KAT6B-KANSL1 fusion transcript (Fig. 3A-B), whereas the reciprocal KANSL1-KAT6B fusion transcript could not be found (data not shown).

The KAT6B gene (in the original article the gene name was MORF) was identified as a KAT6A (also named MOZ)-related gene which displays 60% identity and 66% similarity to MOZ [25]. The KAT6B protein contains an N-terminal region referred to as the NEMM domain (N‐terminal region in Enok, MOZ or MORF), C4HC3 PHD zinc fingers, a histone acetyltransferase (HAT) domain, an acidic region, and a C-terminal ser/met-rich domain, as does KAT6A [25, 26]. The C-terminal part of the NEMM domain displays sequence similarity to the globular domains of linker histones H1 and H5. These H1‐ and H5‐like regions, known as H15 domains, may mediate self‐association and interaction with core histones and nucleosomes since the globular domains of histones H1 and H5 are known to have similar activities [27, 28]. Linker histone H1 is an essential component of chromatin structure. H1 links nucleosomes into higher order structures. Histone H5 performs the same function as histone H1 and replaces H1 in certain cells (

KAT6B was previously shown to be rearranged and fused to CREBBP in an acute myeloid leukemia carrying a t(10;16)(q22;p13) chromosome translocation and then both KAT6B-CREBBP and CREBBP-KAT6B chimeras were expressed [16]. The KAT6B-CREBBP chimeric protein retains the part of KAT6B that encodes the N-terminal region NEMM domain, the PHD zinc fingers, two nuclear localization signals, the HAT domain, and a portion of the acidic domain and the CBP protein downstream of codon 29. In the reciprocal CREBBP-KAT6B fusion transcript, part of the acidic domain of MORF, the ser-rich region, and the highly met-enriched C-terminal part are likely to be driven by the CREBBP promoter [16]. Recently, constitutional mutations in KAT6B were found to cause Genitopatellar syndrome (GPS) and the Say-Barber-Biesecker variant of Ohdo syndrome (SBBYSS) [29, 30]. Mutations leading to GPS occur in the proximal portion of the last exon and lead to the expression of a protein without a C-terminal domain. Mutations leading to SBBYSS occur either throughout the gene, leading to nonsense-mediated decay, or more distally in the last exon [31]. KAT6B was also found to be disrupted in a boy with a Noonan syndrome–like phenotype carrying a balanced constitutional de novo chromosome translocation, t(10;13)(q22.3;q34) [32]. The breakpoint in 10q22.3 disrupted the KAT6B gene within intron 3 after the first coding exon, i.e., the same intron in which the breakpoint was mapped in four uterine leiomyomas with rearrangement of the KAT6B gene [15]. A 50% reduction of mRNA expression levels of KAT6B was confirmed by quantitative RT-PCR in the patient’s leukocytes [32]. Haploinsufficiency of KAT6B impaired histone acetylation and was the underlying cause of the phenotype. The MAPK signaling pathway represents a major target of KAT6B activity and KAT6B insufficiency causes enhanced phosphorylation of several genes in this pathway [32].

The KANSL1 gene encodes, according to the gene database, a nuclear protein that is a subunit of two protein complexes, MLL1 and NSL1, involved in histone acetylation. The corresponding protein in Drosophila interacts with K(lysine) acetyltransferase 8, which is also a subunit of both the MLL1 and NSL1 complexes ( The KANSL1 protein consists of 1105 amino acid residues and contains at its C-terminal end the PEHE domain which interacts with the HAT domain of KAT8 (also known as MOF and MYST1) [33, 34]. Recently, a study on the nonspecific lethal (NSL) complex showed that, within it, KANSL1 acts as a scaffold protein interacting with four other subunits, including WDR5, which in turn binds KANSL2 [35]. Mutations in KANSL1 cause the Koolen de Vries syndrome (also known as the chromosome 17q21.31 microdeletion syndrome) (

In the present study, the KAT6B-KANSL1 fusion transcript, composed of exons 1 to 3 of KAT6B and exons 11 to 15 of KANSL1, is 3667 bp long, has a 1398 bp long open reading frame, and codes for a 466 amino acid residue protein (Fig. 5). The putative KAT6B-KANSL1 fusion protein contains the NEMM domain (including the linker histone H1/H5, domain H15) of KAT6B and the PEHE domain of KANSL1 suggesting an affinity for chromatin (linker histone H1/H5) and interaction with the HAT domain of KAT8 (PEHE domain). The overall function might be regulation of transcription.

Figure 5. The putative 1398 bp open reading frame of KAT6B-KANSL1 and the coded 466 amino acid residue protein.

The junction GC is in red with yellow background and underlined. The four primers MORF-1234F, MORF-1261F, KANSL1–2900R1, and KANSL1–2969R1 are underlined. The H15 linker histone H1/H5 globular (H15) domain profile (green) and PEHE domain (blue) are shown.

At the genomic level, KAT6B is transcribed from centromere to telomere whereas the transcription of KANSL1 proceeds in the opposite direction from telomere to centromere. Hence, the formation of KAT6B-KANSL1 fusion is only possible if another genomic aberration, possibly an inversion, occurs in addition to the chromosome translocation. Such an event would be analogous to the formation of EWSR1-DDIT3 in myxoid liposarcoma, EWSR1-ERG in Ewing sarcoma, and the EPC-PHF1, JAZF1-PHF1, and MEAF6-PHF1 fusions in endometrial stromal sarcoma [3639]. No material was available for FISH examinations to identify on which derivative chromosome the KAT6B-KANSL1 fusion was located. Presumably, though this is something we cannot know, the KAT6B-KANSL1 fusion also existed in the four uterine leiomyomas with rearrangements of 10q and 17q and disruption of the KAT6B previously reported by Moore et al. [15]. The orientation of KAT6B in relation to KANSL1 may also explain the low frequency of the t(10;17)(q22;q21). However, the frequency of KAT6B-KANSL1 fusion might be higher as it could be a pathogenetic candidate of partially cryptic rearrangements of chromosome band 17q21 in the 34 uterine leiomyomas with cytogenetic aberrations involving the q arm of chromosome 10 (especially in the 25 such tumors with the breakpoint assigned to chromosome band 10q22) reported in the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (, Database last updated on May 13, 2014). Moore et al. [15] showed that one of their four studied uterine leiomyomas had a cryptic chromosome 17 rearrangement which could be found by interphase FISH but not by GTG-banding.

Since the three genes HMGA2, HMGA1, and MED12 are known to be frequently involved in the development of uterine leiomyomas, we investigated them, too, in the present tumor with a t(10;17)(q22;q21). HMGA2 is overexpressed in leiomyomas both with and without chromosome rearrangement of 12q14–15 [4042] suggesting a general role of this gene in leiomyoma development [41]. Similarly, overexpression of HMGA1 has been found in uterine leiomyomas both with and without microscopically visible 6p21 aberration [43, 44]. A number of recent studies have reported mutations in exon 2 of the MED12 gene in the majority of uterine leiomyomas (50–70%) [913]. Mutations of MED12 were found in uterine leiomyomas with normal karyotype, deletions or rearrangements of the long arm of chromosome 7 as sole anomaly or 6p21~23 abnormalities leading to HMGA1 rearrangement/overexpression, and it was concluded that the MED12 mutations had preceded the chromosomal aberrations [45]. Mutations of MED12 have, on the other hand, not been detected in uterine leiomyomas with 12q14~15 rearrangements resulting in overexpression of HMGA2 [45, 46]. According to Markowski et al. [45], these data “stratify two mutually exclusive pathways of leiomyomagenesis with either rearrangements of HMGA2 reflected by clonal chromosome abnormalities affecting 12q14~15 or by mutations affecting exon 2 of MED12”. Because uterine leiomyomas with MED12 mutations expressed significantly higher levels of the gene encoding wingless-type MMTV integration site family, member 4 (WNT4), the authors suggested that the MED12 mutations exert their effects by activating the canonical Wnt pathway [45]. In a recent study, MED12 mutations were also found in 34% of leiomyoma/leiomyomatosis in pelvic/retroperitoneal sites but there was no information about the status of HMGA2 and HMGA1 [9].

The examined retroperitoneal leiomyoma in addition to the KAT6B-KANSL1 fusion transcript also expressed HMGA2 and HMGA1 although there were no cytogenetically detectable aberrations of 12q14–15 (HMGA2) and 6p (HMGA1). No evidence of mutations in exon 2 of MED12 was seen. The KAT6B-KANSL1 fusion gene might, thus, represent a third pathway of leiomyomatogenesis involving the MLL1 and NSL1 protein complexes and histone acetylation but without chromosomal changes targeting HMGA-genes and MED12-mutations. Obviously, additional cases must be studied before conclusions can be drawn.

Supporting Information

S1 Table. Fusion transcripts detected using FusionMap.



S2 Table. Fusion transcripts detected using FusionFinder.



Author Contributions

Conceived and designed the experiments: IP. Performed the experiments: IP LG. Analyzed the data: IP LG. Contributed reagents/materials/analysis tools: BB SH. Wrote the paper: IP SH.


  1. 1. Fasih N, Prasad Shanbhogue AK, Macdonald DB, Fraser-Hill MA, Papadatos D, et al. (2008) Leiomyomas beyond the uterus: unusual locations, rare manifestations. Radiographics 28: 1931–1948. doi: 10.1148/rg.287085095. pmid:19001649
  2. 2. Billings SD, Folpe AL, Weiss SW (2001) Do leiomyomas of deep soft tissue exist? An analysis of highly differentiated smooth muscle tumors of deep soft tissue supporting two distinct subtypes. Am J Surg Pathol 25: 1134–1142. doi: 10.1097/00000478-200109000-00003. pmid:11688572
  3. 3. Paal E, Miettinen M (2001) Retroperitoneal leiomyomas: a clinicopathologic and immunohistochemical study of 56 cases with a comparison to retroperitoneal leiomyosarcomas. Am J Surg Pathol 25: 1355–1363. doi: 10.1097/00000478-200111000-00002. pmid:11684951
  4. 4. Poliquin V, Victory R, Vilos GA (2008) Epidemiology, presentation, and management of retroperitoneal leiomyomata: systematic literature review and case report. J Minim Invasive Gynecol 15: 152–160. doi: 10.1016/j.jmig.2007.12.009. pmid:18312983
  5. 5. Dursun P, Salman MC, Taskiran C, Yuce K, Ayhan A (2005) Retroperitoneal leiomyomatosis: a case report. Int J Gynecol Cancer 15: 1222–1225. doi: 10.1111/j.1525-1438.2005.00329.x. pmid:16343219
  6. 6. Kang WD, Kim SM, Kim YH, Choi HS (2009) Three isolated, large retroperitoneal leiomyomas. Arch Gynecol Obstet 280: 499–501. doi: 10.1007/s00404-009-0945-z. pmid:19184074
  7. 7. Stutterecker D, Umek W, Tunn R, Sulzbacher I, Kainz C (2001) Leiomyoma in the space of Retzius: a report of 2 cases. Am J Obstet Gynecol 185: 248–249. doi: 10.1067/mob.2001.114503. pmid:11483940
  8. 8. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (2013) WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC.
  9. 9. Schwetye KE, Pfeifer JD, Duncavage EJ (2014) MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol 45: 65–70. doi: 10.1016/j.humpath.2013.08.005. pmid:24196187
  10. 10. Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, et al. (2011) MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2: 966–969. pmid:22182697
  11. 11. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, et al. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334: 252–255. doi: 10.1126/science.1208930. pmid:21868628
  12. 12. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, et al. (2012) Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 7: e33251. doi: 10.1371/journal.pone.0033251. pmid:22428002
  13. 13. Perot G, Croce S, Ribeiro A, Lagarde P, Velasco V, et al. (2012) MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 7: e40015. doi: 10.1371/journal.pone.0040015. pmid:22768200
  14. 14. Heim S, Mitelman F (2009) Cancer Cytogenetics: Wiley-Blackwell.
  15. 15. Moore SD, Herrick SR, Ince TA, Kleinman MS, Dal Cin P, et al. (2004) Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res 64: 5570–5577. doi: 10.1158/0008-5472.CAN-04-0050. pmid:15313893
  16. 16. Panagopoulos I, Fioretos T, Isaksson M, Samuelsson U, Billstrom R, et al. (2001) Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Genet 10: 395–404. doi: 10.1093/hmg/10.4.395. pmid:11157802
  17. 17. Schaffer LG, Slovak ML, Campbell LJ (2009) ISCN 2009: an International System for Human Cytogenetic Nomenclature. Basel: Karger.
  18. 18. Ge H, Liu K, Juan T, Fang F, Newman M, et al. (2011) FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics 27: 1922–1928. doi: 10.1093/bioinformatics/btr310. pmid:21593131
  19. 19. Francis RW, Thompson-Wicking K, Carter KW, Anderson D, Kees UR, et al. (2012) FusionFinder: a software tool to identify expressed gene fusion candidates from RNA-Seq data. PLoS One 7: e39987. doi: 10.1371/journal.pone.0039987. pmid:22761941
  20. 20. Field D, Tiwari B, Booth T, Houten S, Swan D, et al. (2006) Open software for biologists: from famine to feast. Nat Biotechnol 24: 801–803. doi: 10.1038/nbt0706-801. pmid:16841067
  21. 21. Gorunova L, Bjerkehagen B, Heim S (2011) Paratesticular leiomyoma with a der(14)t(12;14)(q15;q24). Cancer Genet 204: 465–468. doi: 10.1016/j.cancergen.2011.06.005. pmid:21962898
  22. 22. Panagopoulos I, Torkildsen S, Gorunova L, Tierens A, Tjonnfjord GE, et al. (2014) Comparison between Karyotyping-FISH-Reverse Transcription PCR and RNA- Sequencing-Fusion Gene Identification Programs in the Detection of KAT6A-CREBBP in Acute Myeloid Leukemia. PLoS One 9: e96570. doi: 10.1371/journal.pone.0096570. pmid:24798186
  23. 23. Panagopoulos I, Gorunova L, Bjerkehagen B, Heim S (2014) The “Grep” Command But Not FusionMap, FusionFinder or ChimeraScan Captures the CIC-DUX4 Fusion Gene from Whole Transcriptome Sequencing Data on a Small Round Cell Tumor with t(4;19)(q35;q13). PLoS One 9: e99439. doi: 10.1371/journal.pone.0099439. pmid:24950227
  24. 24. Panagopoulos I, Brandal P, Gorunova L, Bjerkehagen B, Heim S (2014) Novel CSF1–S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors. Int J Oncol 44: 1425–1432. doi: 10.3892/ijo.2014.2326. pmid:24604026
  25. 25. Champagne N, Bertos NR, Pelletier N, Wang AH, Vezmar M, et al. (1999) Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. J Biol Chem 274: 28528–28536. doi: 10.1074/jbc.274.40.28528. pmid:10497217
  26. 26. Borrow J, Stanton VP Jr., Andresen JM, Becher R, Behm FG, et al. (1996) The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14: 33–41. doi: 10.1038/ng0996-33. pmid:8782817
  27. 27. Carter GJ, van Holde K (1998) Self-association of linker histone H5 and of its globular domain: evidence for specific self-contacts. Biochemistry 37: 12477–12488. doi: 10.1021/bi980716v. pmid:9730820
  28. 28. Ramakrishnan V, Finch JT, Graziano V, Lee PL, Sweet RM (1993) Crystal structure of globular domain of histone H5 and its implications for nucleosome binding. Nature 362: 219–223. doi: 10.1038/362219a0. pmid:8384699
  29. 29. Campeau PM, Kim JC, Lu JT, Schwartzentruber JA, Abdul-Rahman OA, et al. (2012) Mutations in KAT6B, encoding a histone acetyltransferase, cause Genitopatellar syndrome. Am J Hum Genet 90: 282–289. doi: 10.1016/j.ajhg.2011.11.023. pmid:22265014
  30. 30. Clayton-Smith J, O’Sullivan J, Daly S, Bhaskar S, Day R, et al. (2011) Whole-exome-sequencing identifies mutations in histone acetyltransferase gene KAT6B in individuals with the Say-Barber-Biesecker variant of Ohdo syndrome. Am J Hum Genet 89: 675–681. doi: 10.1016/j.ajhg.2011.10.008. pmid:22077973
  31. 31. Campeau PM, Lu JT, Dawson BC, Fokkema IF, Robertson SP, et al. (2012) The KAT6B-related disorders genitopatellar syndrome and Ohdo/SBBYS syndrome have distinct clinical features reflecting distinct molecular mechanisms. Hum Mutat 33: 1520–1525. doi: 10.1002/humu.22141. pmid:22715153
  32. 32. Kraft M, Cirstea IC, Voss AK, Thomas T, Goehring I, et al. (2011) Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice. J Clin Invest 121: 3479–3491. doi: 10.1172/JCI43428. pmid:21804188
  33. 33. Cai Y, Jin J, Swanson SK, Cole MD, Choi SH, et al. (2010) Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. J Biol Chem 285: 4268–4272. doi: 10.1074/jbc.C109.087981. pmid:20018852
  34. 34. Marín I (2003) Evolution of chromatin-remodeling complexes: comparative genomics reveals the ancient origin of “novel” compensasome genes. J Mol Evol 56: 527–539. doi: 10.1007/s00239-002-2422-1. pmid:12698291
  35. 35. Dias J, Van Nguyen N, Georgiev P, Gaub A, Brettschneider J, et al. (2014) Structural analysis of the KANSL1/WDR5/KANSL2 complex reveals that WDR5 is required for efficient assembly and chromatin targeting of the NSL complex. Genes Dev 28: 929–942. doi: 10.1101/gad.240200.114. pmid:24788516
  36. 36. Micci F, Panagopoulos I, Bjerkehagen B, Heim S (2006) Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 66: 107–112. doi: 10.1158/0008-5472.CAN-05-2485. pmid:16397222
  37. 37. Panagopoulos I, Höglund M, Mertens F, Mandahl N, Mitelman F, et al. (1996) Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 12: 489–494. pmid:8637704 doi: 10.1016/s0165-4608(97)82589-7
  38. 38. Panagopoulos I, Micci F, Thorsen J, Gorunova L, Eibak AM, et al. (2012) Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. PLoS One 7: e39354. doi: 10.1371/journal.pone.0039354. pmid:22761769
  39. 39. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, et al. (1993) Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 12: 4481–4487. pmid:8223458
  40. 40. Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, et al. (2003) HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 38: 68–79. doi: 10.1002/gcc.10240. pmid:12874787
  41. 41. Klemke M, Meyer A, Nezhad MH, Bartnitzke S, Drieschner N, et al. (2009) Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 48: 171–178. doi: 10.1002/gcc.20627. pmid:18980243
  42. 42. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, et al. (2003) Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res 63: 1351–1358. pmid:12649198
  43. 43. Nezhad MH, Drieschner N, Helms S, Meyer A, Tadayyon M, et al. (2010) 6p21 rearrangements in uterine leiomyomas targeting HMGA1. Cancer Genet Cytogenet 203: 247–252. doi: 10.1016/j.cancergencyto.2010.08.005. pmid:21156240
  44. 44. Sornberger KS, Weremowicz S, Williams AJ, Quade BJ, Ligon AH, et al. (1999) Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet Cytogenet 114: 9–16. doi: 10.1016/S0165-4608(99)00054-0. pmid:10526529
  45. 45. Markowski DN, Bartnitzke S, Loning T, Drieschner N, Helmke BM, et al. (2012) MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups. Int J Cancer 131: 1528–1536. doi: 10.1002/ijc.27424. pmid:22223266
  46. 46. Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, et al. (2014) MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol 27: 1144–1153. doi: 10.1038/modpathol.2013.243. pmid:24390224